Enterprise Value

124.8M

Cash

56.33M

Avg Qtr Burn

-9.705M

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

51.68%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Setrusumab Details
Osteogenesis imperfecta

Phase 2

Data readout

MPH-966 (Alvelestat) (oral neutrophil elastase inhibitor) Details
Severe alpha-1 antitrypsin deficiency

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 1/2

Update

Phase 1b

Data readout

Etigilimab Details
Ovarian cancer

Phase 1b

Update